SCHEMBL3015368

SCHEMBL3015368

Cc1cccc(C)c1Cc1csc(N2CCN(S(=O)(=O)c3ccc(F)cc3F)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.46
KMT2A Q03164 5/20 0.46
LMNA P02545 5/20 0.46
MAPT P10636 4/20 0.46
MEN1 O00255 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GBA1 P04062 1/20 0.45
USP2 O75604 2/20 0.44
RECQL P46063 1/20 0.44
HSD17B10 Q99714 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
MAPK1 P28482 4/20 0.43
TSHR P16473 4/20 0.43
HTT P42858 3/20 0.43
PKM P14618 3/20 0.41
POLB P06746 3/20 0.41
GAA P10253 1/20 0.41
RAB9A P51151 1/20 0.40
KDM2B Q8NHM5 1/20 0.39
PKLR P30613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016763 0.93 ALDH1A1 (0.45) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3010905 0.92 ALDH1A1 (0.46) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3003394 0.91 ALDH1A1 (0.47) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3013261 0.90 ALDH1A1 (0.47) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3002474 0.90 GBA1 (0.46) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3003143 0.87 LMNA (0.45) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3023011 0.87 RAB9A (0.48) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3007418 0.86 ALDH1A1 (0.60) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3014062 0.86 ALDH1A1 (0.45) ALDH1A1KMT2ALMNAMAPTMEN1
SCHEMBL3014133 0.86 ALDH1A1 (0.46) ALDH1A1KMT2ALMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885KMT2A 2680/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.